DeltaRex-G Uses, Dosage, Side Effects and more
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
| Trade Name | DeltaRex-G |
| Generic | Rexin G |
| Rexin G Other Names | DeltaRex-G, DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor, Mx-dnG1 retroviral vector, retroviral expression vector bearing anti-cyclin G1 gene construct, Rexin-G |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How DeltaRex-G works
DeltaRex-G is a non-pathogenic entity that mimics SARS-COV2 by binding to receptors to gain entry into human cells. It is being investigated for preventing SARSCOV-2 viral entry, and also acts as an inhibitor of the cyclin G1 pathway.
